BN/SsNHsd |
percentage of study population developing pituitary tumors that replace a portion of the gland during a period of time |
diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days) |
Pandey J, et al., Carcinogenesis 2004 May 27;. |
pituitary gland integrity trait |
not specified |
91 days
| 6 |
0.0 |
% |
|
|
ex vivo light microscopy |
0.0 |
surgery implant |
70 |
days |
xco:0000295 |
|
69909 |
1240 |
BN/SsNHsd |
percentage of study population developing pituitary tumors that replace the entire gland during a period of time |
diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days) |
Pandey J, et al., Carcinogenesis 2004 May 27;. |
pituitary gland integrity trait |
not specified |
91 days
| 6 |
0.0 |
% |
|
|
ex vivo light microscopy |
0.0 |
surgery implant |
70 |
days |
xco:0000295 |
|
69910 |
1240 |
F344/NHsd |
percentage of study population developing pituitary tumors that invade the glandular capsule during a period of time |
diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days) |
Pandey J, et al., Carcinogenesis 2004 May 27;. |
pituitary gland integrity trait |
not specified |
91 days
| 6 |
50.0 |
% |
|
|
ex vivo light microscopy |
0.0 |
surgery implant |
70 |
days |
xco:0000295 |
|
69915 |
1240 |
F344/Stm |
both testes wet weight |
diethylstilbestrol (17 mg) (for 84 days) |
Tachibana M, et al., Exp Anim. 2006 Apr;55(2):91-5. |
testis mass |
male |
112 days
| 0 |
0.2 |
g |
|
0.01 |
post excision weight measurement |
0.0 |
|
0 |
|
|
|
69881 |
1218 |
F344.BN-(D3Mgh13-D3Mgh7)/Dlw |
lactotroph count to total pituicyte count ratio in prolactinoma |
diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days) |
Pandey J and Wendell DL, Mamm Genome. 2006 Jan;17(1):49-57. Epub 2006 Jan 13. |
pituitary gland integrity trait |
female |
91 days
| 0 |
93.4 |
% |
|
|
ex vivo light microscopy with immunohistochemistry |
0.0 |
subcutaneous implant |
70 |
days |
|
|
97079 |
1838 |
COP/CrCrl |
pituitary gland wet weight |
diethylstilbestrol (5 mg) (for 84 days) and surgical implantation |
Strecker TE, et al., Genetics 2005 Jan 31;. |
pituitary gland mass |
male |
147 days
| 28 |
0.04 |
g |
0.0 |
0.01 |
post excision weight measurement |
0.0 |
subcutaneous implant |
84 |
days |
diethylstilbestrol |
|
69107 |
1122 |
BN/SsNHsd |
percentage of study population developing pituitary tumors that invade the glandular capsule during a period of time |
diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days) |
Pandey J, et al., Carcinogenesis 2004 May 27;. |
pituitary gland integrity trait |
not specified |
91 days
| 6 |
0.0 |
% |
|
|
ex vivo light microscopy |
0.0 |
surgery implant |
70 |
days |
xco:0000295 |
|
69911 |
1240 |
F344/NHsd |
percentage of study population developing pituitary gland hyperplastic lesions during a period of time |
diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days) |
Pandey J, et al., Carcinogenesis 2004 May 27;. |
pituitary gland integrity trait |
not specified |
91 days
| 6 |
0.0 |
% |
|
|
ex vivo light microscopy |
0.0 |
surgery implant |
70 |
days |
xco:0000295 |
|
69912 |
1240 |
F344.BN-(D5Rat1-D5Mit5)/Dlw |
percentage of study population developing pituitary tumors that invade the glandular capsule during a period of time |
diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days) |
Pandey J, et al., Carcinogenesis 2004 May 27;. |
pituitary gland integrity trait |
not specified |
91 days
| 6 |
67.0 |
% |
|
|
ex vivo light microscopy |
0.0 |
surgery implant |
70 |
days |
xco:0000295 |
|
69919 |
1240 |
F344/NHsd |
percentage of study population developing pituitary tumors that replace the entire gland during a period of time |
diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days) |
Pandey J, et al., Carcinogenesis 2004 May 27;. |
pituitary gland integrity trait |
not specified |
91 days
| 6 |
50.0 |
% |
|
|
ex vivo light microscopy |
0.0 |
surgery implant |
70 |
days |
xco:0000295 |
|
69914 |
1240 |
F344.BN-(D5Rat1-D5Mit5)/Dlw |
percentage of study population developing pituitary tumors that replace a portion of the gland during a period of time |
diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days) |
Pandey J, et al., Carcinogenesis 2004 May 27;. |
pituitary gland integrity trait |
not specified |
91 days
| 6 |
67.0 |
% |
|
|
ex vivo light microscopy |
0.0 |
surgery implant |
70 |
days |
xco:0000295 |
|
69917 |
1240 |
F344.BN-(D5Rat1-D5Mit5)/Dlw |
percentage of study population developing pituitary tumors that replace the entire gland during a period of time |
diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days) |
Pandey J, et al., Carcinogenesis 2004 May 27;. |
pituitary gland integrity trait |
not specified |
91 days
| 6 |
33.0 |
% |
|
|
ex vivo light microscopy |
0.0 |
surgery implant |
70 |
days |
xco:0000295 |
|
69918 |
1240 |
F344.BN-(D5Rat1-D5Mit5)/Dlw |
lactotroph count to total pituicyte count ratio in prolactinoma |
diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days) |
Pandey J, et al., Carcinogenesis 2004 May 27;. |
pituitary gland integrity trait |
not specified |
91 days
| 6 |
86.0 |
% |
9.0 |
22.05 |
ex vivo light microscopy |
0.0 |
surgery implant |
70 |
days |
xco:0000295 |
lactotroph to total pituicyte ratio |
69920 |
1240 |
ACI/SegHsd |
pituitary gland wet weight |
diethylstilbestrol (5 mg) (for 84 days) and surgical implantation |
Strecker TE, et al., Genetics 2005 Jan 31;. |
pituitary gland mass |
male |
147 days
| 14 |
0.08 |
g |
0.0 |
0.01 |
post excision weight measurement |
0.0 |
subcutaneous implant |
84 |
days |
diethylstilbestrol |
|
69101 |
1122 |
COP/CrCrl |
pituitary gland wet weight |
diethylstilbestrol (5 mg) (for 84 days) and surgical implantation |
Strecker TE, et al., Genetics 2005 Jan 31;. |
pituitary gland mass |
male |
147 days
| 14 |
0.03 |
g |
0.0 |
0.01 |
post excision weight measurement |
0.0 |
subcutaneous implant |
84 |
days |
diethylstilbestrol |
|
69103 |
1122 |
ACI/SegHsd |
pituitary gland wet weight |
diethylstilbestrol (5 mg) (for 84 days) and surgical implantation |
Strecker TE, et al., Genetics 2005 Jan 31;. |
pituitary gland mass |
male |
147 days
| 28 |
0.07 |
g |
0.0 |
0.01 |
post excision weight measurement |
0.0 |
subcutaneous implant |
84 |
days |
diethylstilbestrol |
|
69105 |
1122 |
F344/NHsd |
lactotroph count to total pituicyte count ratio in prolactinoma |
diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days) |
Pandey J and Wendell DL, Mamm Genome. 2006 Jan;17(1):49-57. Epub 2006 Jan 13. |
pituitary gland integrity trait |
female |
91 days
| 0 |
99.1 |
% |
|
|
ex vivo light microscopy with immunohistochemistry |
0.0 |
subcutaneous implant |
70 |
days |
|
|
97077 |
1838 |
BN/SsNHsd |
percentage of study population developing pituitary gland hyperplastic lesions during a period of time |
diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days) |
Pandey J, et al., Carcinogenesis 2004 May 27;. |
pituitary gland integrity trait |
not specified |
91 days
| 6 |
100.0 |
% |
|
|
ex vivo light microscopy |
0.0 |
surgery implant |
70 |
days |
xco:0000295 |
|
69908 |
1240 |
F344/NHsd |
percentage of study population developing pituitary tumors that replace a portion of the gland during a period of time |
diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days) |
Pandey J, et al., Carcinogenesis 2004 May 27;. |
pituitary gland integrity trait |
not specified |
91 days
| 6 |
50.0 |
% |
|
|
ex vivo light microscopy |
0.0 |
surgery implant |
70 |
days |
xco:0000295 |
|
69913 |
1240 |
F344.BN-(D5Rat1-D5Mit5)/Dlw |
percentage of study population developing pituitary gland hyperplastic lesions during a period of time |
diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days) |
Pandey J, et al., Carcinogenesis 2004 May 27;. |
pituitary gland integrity trait |
not specified |
91 days
| 6 |
0.0 |
% |
|
|
ex vivo light microscopy |
0.0 |
surgery implant |
70 |
days |
xco:0000295 |
|
69916 |
1240 |
BN/SsNHsd |
thymus wet weight |
diethylstilbestrol (5 mg) (for 84 days) and surgical implantation |
Gould KA, et al., Mamm Genome. 2006 May;17(5):451-64. |
thymus mass |
male |
147 days
| 15 |
66.0 |
mg |
4.39 |
17.0 |
post excision weight measurement |
0.0 |
subcutaneous implant |
84 |
days |
diethylstilbestrol |
|
69095 |
1121 |
ACI/SegHsd |
thymus wet weight |
diethylstilbestrol (5 mg) (for 84 days) and surgical implantation |
Gould KA, et al., Mamm Genome. 2006 May;17(5):451-64. |
thymus mass |
male |
147 days
| 13 |
166.0 |
mg |
6.1 |
22.0 |
post excision weight measurement |
0.0 |
subcutaneous implant |
84 |
days |
diethylstilbestrol |
|
69099 |
1121 |
LE/Stm |
both testes wet weight |
diethylstilbestrol (17 mg) (for 84 days) |
Tachibana M, et al., Exp Anim. 2006 Apr;55(2):91-5. |
testis mass |
male |
112 days
| 0 |
0.15 |
g |
|
0.01 |
post excision weight measurement |
0.0 |
|
0 |
|
|
|
69879 |
1218 |